GLPG-0492

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
GLPG-0492
Accession Number
DB12461
Type
Small Molecule
Groups
Investigational
Description

Glpg0492 is under investigation in clinical trial NCT01130818 (First-in-Human Single Ascending Dose of GLPG0492).

Structure
Thumb
Synonyms
Not Available
External IDs
(-)-GLPG-0492 / GLPG0492
Categories
UNII
8O59X1ACZT
CAS number
1215085-92-9
Weight
Average: 389.334
Monoisotopic: 389.098725812
Chemical Formula
C19H14F3N3O3
InChI Key
VAJGULUVTFDTAS-GOSISDBHSA-N
InChI
InChI=1S/C19H14F3N3O3/c1-24-17(28)25(14-8-7-12(10-23)15(9-14)19(20,21)22)16(27)18(24,11-26)13-5-3-2-4-6-13/h2-9,26H,11H2,1H3/t18-/m1/s1
IUPAC Name
4-[(4S)-4-(hydroxymethyl)-3-methyl-2,5-dioxo-4-phenylimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
SMILES
CN1C(=O)N(C(=O)[[email protected]@]1(CO)C1=CC=CC=C1)C1=CC=C(C#N)C(=C1)C(F)(F)F

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the fluid retaining activities of GLPG-0492.Investigational
19-norandrostenedione19-norandrostenedione may increase the fluid retaining activities of GLPG-0492.Experimental, Illicit
5-androstenedione5-androstenedione may increase the fluid retaining activities of GLPG-0492.Experimental, Illicit
AcenocoumarolGLPG-0492 may increase the anticoagulant activities of Acenocoumarol.Approved
AlclometasoneAlclometasone may increase the fluid retaining activities of GLPG-0492.Approved
AldosteroneAldosterone may increase the fluid retaining activities of GLPG-0492.Experimental, Investigational
AmcinonideAmcinonide may increase the fluid retaining activities of GLPG-0492.Approved
AndrostenedioneAndrostenedione may increase the fluid retaining activities of GLPG-0492.Experimental, Illicit
AnecortaveAnecortave may increase the fluid retaining activities of GLPG-0492.Investigational
anecortave acetateanecortave acetate may increase the fluid retaining activities of GLPG-0492.Investigational
AtamestaneAtamestane may increase the fluid retaining activities of GLPG-0492.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the fluid retaining activities of GLPG-0492.Approved, Investigational
BetamethasoneBetamethasone may increase the fluid retaining activities of GLPG-0492.Approved, Vet Approved
BudesonideBudesonide may increase the fluid retaining activities of GLPG-0492.Approved
CiclesonideCiclesonide may increase the fluid retaining activities of GLPG-0492.Approved, Investigational
ClobetasolClobetasol may increase the fluid retaining activities of GLPG-0492.Investigational
Clobetasol propionateClobetasol propionate may increase the fluid retaining activities of GLPG-0492.Approved
ClobetasoneClobetasone may increase the fluid retaining activities of GLPG-0492.Approved
ClocortoloneClocortolone may increase the fluid retaining activities of GLPG-0492.Approved
ClorindioneGLPG-0492 may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the fluid retaining activities of GLPG-0492.Investigational
CorticosteroneCorticosterone may increase the fluid retaining activities of GLPG-0492.Experimental
Cortisone acetateCortisone acetate may increase the fluid retaining activities of GLPG-0492.Approved
CyclosporineGLPG-0492 may increase the hepatotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
DeflazacortDeflazacort may increase the fluid retaining activities of GLPG-0492.Approved, Investigational
DesonideDesonide may increase the fluid retaining activities of GLPG-0492.Approved, Investigational
DesoximetasoneDesoximetasone may increase the fluid retaining activities of GLPG-0492.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the fluid retaining activities of GLPG-0492.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the fluid retaining activities of GLPG-0492.Experimental, Vet Approved
DexamethasoneDexamethasone may increase the fluid retaining activities of GLPG-0492.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the fluid retaining activities of GLPG-0492.Vet Approved
DicoumarolGLPG-0492 may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneDiflorasone may increase the fluid retaining activities of GLPG-0492.Approved
DifluocortoloneDifluocortolone may increase the fluid retaining activities of GLPG-0492.Approved, Investigational, Withdrawn
DifluprednateDifluprednate may increase the fluid retaining activities of GLPG-0492.Approved
DiphenadioneGLPG-0492 may increase the anticoagulant activities of Diphenadione.Experimental
EquileninEquilenin may increase the fluid retaining activities of GLPG-0492.Experimental
EquilinEquilin may increase the fluid retaining activities of GLPG-0492.Approved
EstroneEstrone may increase the fluid retaining activities of GLPG-0492.Approved
Estrone sulfateEstrone sulfate may increase the fluid retaining activities of GLPG-0492.Approved
Ethyl biscoumacetateGLPG-0492 may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
FluasteroneFluasterone may increase the fluid retaining activities of GLPG-0492.Investigational
FludrocortisoneFludrocortisone may increase the fluid retaining activities of GLPG-0492.Approved
FluindioneGLPG-0492 may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneFlumethasone may increase the fluid retaining activities of GLPG-0492.Approved, Vet Approved
FlunisolideFlunisolide may increase the fluid retaining activities of GLPG-0492.Approved, Investigational
Fluocinolone AcetonideFluocinolone Acetonide may increase the fluid retaining activities of GLPG-0492.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the fluid retaining activities of GLPG-0492.Approved, Investigational
FluocortoloneFluocortolone may increase the fluid retaining activities of GLPG-0492.Approved, Withdrawn
FluorometholoneFluorometholone may increase the fluid retaining activities of GLPG-0492.Approved
FluprednideneFluprednidene may increase the fluid retaining activities of GLPG-0492.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the fluid retaining activities of GLPG-0492.Approved
FlurandrenolideFlurandrenolide may increase the fluid retaining activities of GLPG-0492.Approved
Fluticasone furoateFluticasone furoate may increase the fluid retaining activities of GLPG-0492.Approved
Fluticasone propionateFluticasone propionate may increase the fluid retaining activities of GLPG-0492.Approved
FormestaneFormestane may increase the fluid retaining activities of GLPG-0492.Approved, Investigational, Withdrawn
HalcinonideHalcinonide may increase the fluid retaining activities of GLPG-0492.Approved, Investigational, Withdrawn
HE3286HE3286 may increase the fluid retaining activities of GLPG-0492.Investigational
HydrocortisoneHydrocortisone may increase the fluid retaining activities of GLPG-0492.Approved, Vet Approved
IstaroximeIstaroxime may increase the fluid retaining activities of GLPG-0492.Investigational
LoteprednolLoteprednol may increase the fluid retaining activities of GLPG-0492.Approved
ME-609ME-609 may increase the fluid retaining activities of GLPG-0492.Investigational
MedrysoneMedrysone may increase the fluid retaining activities of GLPG-0492.Approved
MelengestrolMelengestrol may increase the fluid retaining activities of GLPG-0492.Vet Approved
MethylprednisoloneMethylprednisolone may increase the fluid retaining activities of GLPG-0492.Approved, Vet Approved
MometasoneMometasone may increase the fluid retaining activities of GLPG-0492.Approved, Vet Approved
NCX 1022NCX 1022 may increase the fluid retaining activities of GLPG-0492.Investigational
Oleoyl-estroneOleoyl-estrone may increase the fluid retaining activities of GLPG-0492.Investigational
ParamethasoneParamethasone may increase the fluid retaining activities of GLPG-0492.Approved
PhenindioneGLPG-0492 may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonGLPG-0492 may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PrasteronePrasterone may increase the fluid retaining activities of GLPG-0492.Approved, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the fluid retaining activities of GLPG-0492.Investigational
PrednicarbatePrednicarbate may increase the fluid retaining activities of GLPG-0492.Approved
PrednisolonePrednisolone may increase the fluid retaining activities of GLPG-0492.Approved, Vet Approved
PrednisonePrednisone may increase the fluid retaining activities of GLPG-0492.Approved, Vet Approved
PregnenolonePregnenolone may increase the fluid retaining activities of GLPG-0492.Experimental, Investigational
RimexoloneRimexolone may increase the fluid retaining activities of GLPG-0492.Approved
TioclomarolGLPG-0492 may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolTixocortol may increase the fluid retaining activities of GLPG-0492.Approved, Withdrawn
TriamcinoloneTriamcinolone may increase the fluid retaining activities of GLPG-0492.Approved, Vet Approved
UlobetasolUlobetasol may increase the fluid retaining activities of GLPG-0492.Approved
WarfarinGLPG-0492 may increase the anticoagulant activities of Warfarin.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
59317190
PubChem Substance
347828700
ChemSpider
28661578
ChEMBL
CHEMBL2178100

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedTreatmentHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00522 mg/mLALOGPS
logP2.48ALOGPS
logP2.71ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)14.44ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area84.64 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity92.93 m3·mol-1ChemAxon
Polarizability35.33 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azolidines
Sub Class
Imidazolidines
Direct Parent
Phenylhydantoins
Alternative Parents
Phenylimidazolidines / Trifluoromethylbenzenes / Alpha amino acids and derivatives / Benzonitriles / N-acyl ureas / Dicarboximides / Nitriles / Azacyclic compounds / Primary alcohols / Organopnictogen compounds
show 5 more
Substituents
3-phenylhydantoin / 5-phenylhydantoin / Phenylimidazolidine / Alpha-amino acid or derivatives / Trifluoromethylbenzene / Benzonitrile / N-acyl urea / Ureide / Monocyclic benzene moiety / Benzenoid
show 22 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 16:29 / Updated on December 01, 2017 16:30